Summary
Calcitonin (CT) constitutes one of the major choices for the pharmacologic treatment of postmenopausal and senile osteoporosis. In postmenopausal osteoporosis, CT, analogous to estrogens, determines increase of bone mass, improvement of intestinal calcium absorption and a positivization of calcium balance. Patients treated with CT can also benefit from the analgesic effect of the hormone. Unlike estrogens, these beneficial effects of CT occur with minimal risk and require no routine gynecological monitoring. In addition, CT is completely devoid of toxicity. The only limitations to the use of CT are linked to the frequent parenteral injections and the occurrence of side effects. These limitations can now be overcome by the availability of the new nasal spray preparation, which has been developed for synthetic salmon calcitonin (sCT). The introduction of this new form increases the patients' compliance, and the different pharmacokinetic curtails the side effects, compared to the parenteral administration. At present, one-year controlled studies have been reported, showing a beneficial effect of sCT on bone mass in patients with established osteoporosis. Also, shorter studies demonstrate the analgesic activity of sCT treatment in patients with vertebral crush fractures and bone pain. The improvement in the patients' compliance and the reduction of side effects allow this new CT preparation to be used in the prevention of post-menopausal osteoporosis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Deftos, L.J., Weisman, M.H., Williams, G.W., Karpf, D.B., Frumar, A.M., Davidson, B.J., Parthemore, on plasma calcitonin in human beings. N Engl J Med 1980, 302, 1351–1353.
Stevenson, J.C., White, M.C., Joplin, G.F., MacIntyre, I. Osteoporosis and calcitonin deficiency. Br Med J 1982, 2852, 1010–1011.
Tgorring, O., Bucht, E., Sjoberg, H.E. Plasma calcitonin response to a calcium clamp. Influence of sex and age. Horm Metabol Res 1985, 17, 536–539.
Greenberg, C., Kukreja, S.C., Bowser, E.N., Hargis, G.K., Henderson, W.J., Williams, G.A. Effects of estradiol and progesterone on calcitonin secretion. Endocrinology 1986, 118, 2594–2598.
Gruber, H.E., Ivey, J.L., Baylink, D.J., Matthews, M., Nelp, W.B., Sisom, K., Chesnut, C.H. Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism 1984, 33, 295–303.
Mazzuoli, G.F., Passeri, M., Gennari, C., Minisola, S., Antonelli, R., Valtorta, C., Palummeri, E., Cervellin, G.F., Gonnelli, S., Francini, G. Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study. Calcif Tissue Int 1986, 38, 3–8.
Gennari, C., Chierichetti, S.M., Bigazzi, S., Fusi, L., Gonnelli, S., Gerrara, R., Zacchei, F. Comparative effects on bone mineral content of calcium and calcium plus salmon calcitonin given in two different regimens in postmenopausal osteoporosis. Curr Ther Res 1985, 38, 455–464.
Aloia, J.F., Vaswani, A., Kapoor, A., Yeh, J.K., Cohn, S.H. Treatment of osteoporosis with calcitonin, with and without growth hormone. Metabolism 1985, 34, 124–129.
Gennari, C., Montagnani, M., Nardi, P., Zacchei, F., Bigazzi, S., Cepollaro, C. Long-term effect of cyclic or continuous calcitonin treatment on bone mass in established postmenopausal osteoporosis. In: Osteoporosis 1987. Eds: Christansen, C., Johansen, J.S., Riis, B.J., Viborg, Norhaven A/S, 1987, 919–921.
Civitelli, R., Gonnelli, S., Zacchei, F., Bigazzi, S., Vattimo, A., Avioli, L.V., Gennari, C. Bone turnover in postmenopausal osteoporosis: effect of calcitonin treatment. J Clin Invest 1988 (in press).
Civitelli, R., Agnusdei, D., Gonnelli, S., Avioli, L.V., Gennari, C. Effect of nandrolone decanoate and salmon calcitonin in combination on bone mass in postmenopausal osteoporosis. In: Laurence and Dorothy Fallis International Symposium on Clinical Disorders of Bone and Mineral Metabolism, Detroit, Michigan, May 8–13, 1988, Abstracts Book 1988, 24.
Gennari, C., Avioli, L.V. Calcitonin therapy in osteoporosis. In: The Osteoporotic Syndrome, Ed: Avioli, L.V., Grune & Stratton, New York, 1987, 121–140.
Christiansen, C., Riis, B.J., Podenphant, J., Johansen, J.S. Intranasal calcitonin in the treatment of postmenopausal osteoporosis. In: Osteoporosis 1987. Eds: Christiansen, C., Johansen, J.S., Riis, B.J., Viborg, Norhaven A/S, 1987, 853–856.
Reginster, J.Y., Denis, D., Albert, A., Deroisy, R., Lecart, M.P., Fontaine, M.A., Lambelin, P., Franchimont, P. A year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet 1987, ii, 1481–1483.
Gennari, C., Chierichetti, S.M., Piolini, M., Vibelli, C., Agnusdei, D., Civitelli, R., Gonnelli, S. Analgesic activity of salmon and human calcitonin against cancer pain: a double-blind placebo-controlled clinical study. Curr Ther Res 1985, 38, 298–308.
Gennari, C. Unpublished data.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gennari, C. Salmon calcitonin (Miacalcic) nasal spray in prevention and treatment of osteoporosis. Clin Rheumatol 8 (Suppl 2), 61–65 (1989). https://doi.org/10.1007/BF02207236
Issue Date:
DOI: https://doi.org/10.1007/BF02207236